Pharmaceutical Executive October 17, 2024
Partnership is expected to develop radioligand therapies based on lead-212 alpha-emitting isotopes, which offer the opportunity to destroy cancer cells with minimal damage to healthy tissue.
Sanofi and Orano Med announced that they have agreed to terms on co-developing radioligand therapies (RLTs) for rare cancers. According to Sanofi, the joint venture aims to revolutionize treatment options for patients with difficult-to-treat cancers.
Operating under the Orano Med brand, the collaboration will also focus on the discovery, design, and clinical development of RLTs based on lead-212 alpha-emitting isotopes, which have the potential to destroy cancer cells with little damage to healthy tissue. This agreement follows news of an exclusive licensing agreement with Orano Med and RadioMedix to advance RLTs in rare cancers...
Today's Sponsors
Today's Sponsor